4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide has been researched along with Diabetes Mellitus, Adult-Onset in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leánez, S; McDonnell, C; Pol, O | 1 |
1 other study(ies) available for 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The induction of the transcription factor Nrf2 enhances the antinociceptive effects of delta-opioid receptors in diabetic mice.
Topics: Animals; Benzamides; Blood Glucose; Blotting, Western; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enkephalin, D-Penicillamine (2,5)-; Hyperalgesia; Isothiocyanates; Male; Mice; NF-E2-Related Factor 2; Piperazines; Receptors, Opioid, delta; Sulfoxides | 2017 |